UPDATED May 14, 2024
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
GTHX | US$4.65 | 9.4% | 71.6% | US$241.5m | US$8.50 | PS2.9x | E48.3% | n/a | Pharmaceuticals & Biotech | ||
ACTD | US$7.79 | -24.2% | -21.2% | US$303.0m | US$17.00 | PE-25.3x | E85.2% | n/a | Diversified Financials | ||
MIST | US$1.72 | -1.1% | -56.1% | US$106.6m | US$13.00 | PB2.7x | E54.7% | n/a | Pharmaceuticals & Biotech | ||
ACHV | US$5.01 | 5.9% | -36.6% | US$164.8m | US$19.75 | PB3.5x | E59.3% | n/a | Pharmaceuticals & Biotech | ||
AZ | US$0.41 | 10.6% | -75.9% | US$22.6m | US$18.00 | PS1.9x | E75.4% | n/a | Capital Goods | ||
SONM | US$0.58 | 6.6% | -45.3% | US$25.3m | US$2.00 | PB1.1x | E139.9% | n/a | Tech | ||
OCUP | US$1.70 | -12.4% | -65.2% | US$43.0m | US$19.33 | PS2.3x | E51.0% | n/a | Pharmaceuticals & Biotech | ||
ZYNE | US$1.30 | 4.0% | 96.1% | US$65.6m | US$1.26 | PB2.3x | E67.2% | n/a | Pharmaceuticals & Biotech | ||
ZVRA | US$4.80 | -7.2% | 2.8% | US$204.7m | US$19.00 | PS7.2x | E65.3% | n/a | Pharmaceuticals & Biotech | ||
IVVD | US$2.43 | -3.2% | 62.0% | US$282.6m | US$11.33 | PB1.6x | E60.0% | n/a | Pharmaceuticals & Biotech | ||
IREN | US$4.87 | -3.9% | 24.2% | US$684.3m | US$11.00 | PS5.6x | E110.2% | n/a | Software | ||
AQMS | US$0.47 | -3.9% | -54.3% | US$54.2m | US$3.00 | PS2130.9x | E63.4% | n/a | Commercial Services | ||
CBST.F | US$0.28 | 0.2% | -39.6% | US$132.6m | US$1.04 | PB2.9x | E99.9% | n/a | Pharmaceuticals & Biotech | ||
AMPG | US$2.18 | -4.4% | -10.7% | US$21.4m | US$9.00 | PS1.4x | E107.0% | n/a | Tech | ||
XELB | US$0.72 | -6.2% | -6.5% | US$16.7m | US$3.00 | PB0.3x | E114.9% | n/a | Retail | ||
PGEN | US$1.37 | -0.7% | 12.3% | US$340.8m | US$6.50 | PS55.6x | E55.5% | n/a | Pharmaceuticals & Biotech | ||
SMSI | US$2.79 | 11.2% | -71.9% | US$26.2m | US$14.67 | PB0.6x | E84.7% | n/a | Software | ||
SCPH | US$4.50 | -8.2% | -58.9% | US$156.8m | US$19.50 | PS11.9x | E59.8% | n/a | Pharmaceuticals & Biotech | ||
ETON | US$3.63 | -2.4% | 0.8% | US$91.2m | US$8.00 | PE102.1x | E117.7% | n/a | Pharmaceuticals & Biotech | ||
PESI | US$12.43 | 2.6% | 6.6% | US$167.1m | US$19.00 | PS2x | E169.3% | n/a | Commercial Services | ||
ALIM | US$3.28 | -8.1% | 74.5% | US$182.2m | US$8.00 | PS2.1x | E58.0% | n/a | Pharmaceuticals & Biotech | ||
DTST | US$5.71 | 1.2% | 202.1% | US$38.8m | US$9.00 | PE103.6x | E65.4% | n/a | Software | ||
ARBB | US$0.91 | -13.3% | -78.3% | US$24.2m | US$3.00 | PB1.1x | E139.1% | n/a | Software | ||
TVTX | US$6.70 | -0.7% | -59.3% | US$482.7m | US$14.86 | PS3.3x | E67.7% | n/a | Pharmaceuticals & Biotech |